• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Vascular adhesion protein-1 (VAP-1) in vascular inflammatory diseases
Vasa. 2022 Oct 6. doi: 10.1024/0301-1526/a001031. Online ahead of print.ABSTRACT Vascular adhesion protein-1 (VAP-1) also known as amino oxidase copper containing 3 (AOC3) is a pro-inflammatory and versatile molecule with adhesive and enzymatic properties. VAP-1 is a primary amine oxidase belonging to the semicarbazide-sensitive amine oxidase (SSAO) family, which catalyzes the oxidation of primary amines leading to the production of ammonium, formaldehyde, methylglyoxal, and hydrogen peroxide. VAP-1 is mainly expressed by endothelial cells, smooth muscle cells, adipocytes and pericytes. It is involved in a repertoire of bi...
Source: VASA. Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases - October 6, 2022 Category: Surgery Authors: Marianna Danielli Roisin Clare Thomas Lauren Marie Quinn Bee Kang Tan Source Type: research

Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin
Venous thromboembolism occurs in up to one-third of patients with primary brain tumors. Spontaneous intracranial hemorrhage (ICH) is also a frequent occurrence in these patients, but there is limited data on the safety of therapeutic anticoagulation. To determine the rate of ICH in patients treated with enoxaparin, we performed a matched, retrospective cohort study with blinded radiology review for 133 patients with high-grade glioma. After diagnosis of glioma, the cohort that received enoxaparin was 3 times more likely to develop a major ICH than those not treated with anticoagulation (14.7% vs 2.5%; P = .036; hazard rati...
Source: Blood - June 22, 2017 Category: Hematology Authors: Mantia, C., Uhlmann, E. J., Puligandla, M., Weber, G. M., Neuberg, D., Zwicker, J. I. Tags: Free Research Articles, Thrombosis and Hemostasis, Clinical Trials and Observations Source Type: research

CDKN2B-AS1: An indispensable long non-coding RNA in multiple diseases.
CONCLUSIONS: Long non-coding RNA CDKN2B-AS1 likely serves as a promising therapeutic target or prognosis biomarker in multiple human diseases. PMID: 32767927 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - August 4, 2020 Category: Drugs & Pharmacology Authors: Song C, Qi Y, Zhang J, Guo C, Yuan C Tags: Curr Pharm Des Source Type: research

Pages: 1  2